Free Trial

Nurix Therapeutics (NRIX) Stock Forecast & Price Target

$21.09
-1.51 (-6.68%)
(As of 07/24/2024 ET)

Nurix Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 11 Wall Street analysts who have issued ratings for Nurix Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 1 has given a hold rating, and 10 have given a buy rating for NRIX.

Consensus Price Target

$25.82
22.42% Upside
High Forecast$35.00
Average Forecast$25.82
Low Forecast$10.00

According to the 11 analysts' twelve-month price targets for Nurix Therapeutics, the average price target is $25.82. The highest price target for NRIX is $35.00, while the lowest price target for NRIX is $10.00. The average price target represents a forecasted upside of 22.42% from the current price of $21.09.

TypeCurrent Forecast
7/25/23 to 7/24/24
1 Month Ago
6/25/23 to 6/24/24
3 Months Ago
4/26/23 to 4/25/24
1 Year Ago
7/25/22 to 7/25/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
9 Buy rating(s)
5 Buy rating(s)
8 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$25.82$24.80$21.33$27.22
Forecasted Upside22.42% Upside71.20% Upside64.59% Upside150.43% Upside
Get Nurix Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter.

NRIX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NRIX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Nurix Therapeutics Stock vs. The Competition

TypeNurix TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.91
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside22.42% Upside3,003.08% Upside10.61% Upside
News Sentiment RatingPositive News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/15/2024JPMorgan Chase & Co.
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$31.00 ➝ $34.00+43.10%
7/15/2024Barclays
2 of 5 stars
 Boost TargetOverweight ➝ Overweight$20.00 ➝ $31.00+29.17%
7/12/2024Royal Bank of Canada
4 of 5 stars
 Boost TargetOutperform ➝ Outperform$26.00 ➝ $27.00+22.12%
7/12/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$31.00 ➝ $29.00+31.64%
6/18/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$19.00 ➝ $26.00+70.05%
6/5/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$35.00 ➝ $35.00+113.94%
5/15/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$27.00+80.60%
5/14/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Loganathan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$20.00+43.47%
4/11/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$24.00 ➝ $25.00+59.34%
2/26/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$9.00 ➝ $10.00-11.35%
2/16/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$23.00 ➝ $20.00+100.80%
2/27/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$25.00+178.40%
12/13/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$37.00 ➝ $28.00+126.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:05 PM ET.

NRIX Forecast - Frequently Asked Questions

What is Nurix Therapeutics' forecast for 2024?

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Nurix Therapeutics is $25.82, with a high forecast of $35.00 and a low forecast of $10.00.

Should I buy or sell Nurix Therapeutics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nurix Therapeutics in the last year. There is currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NRIX shares.

Does Nurix Therapeutics's stock price have much upside?

According to analysts, Nurix Therapeutics's stock has a predicted upside of 49.97% based on their 12-month stock forecasts.

What analysts cover Nurix Therapeutics?

Nurix Therapeutics has been rated by research analysts at Barclays, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Piper Sandler, Royal Bank of Canada, Stephens, and Stifel Nicolaus in the past 90 days.

Do Wall Street analysts like Nurix Therapeutics more than its competitors?

Analysts like Nurix Therapeutics more than other "medical" companies. The consensus rating score for Nurix Therapeutics is 2.91 while the average consensus rating score for "medical" companies is 2.72. Learn more on how NRIX compares to other companies.


This page (NASDAQ:NRIX) was last updated on 7/24/2024 by MarketBeat.com Staff

From Our Partners